Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) presented initial findings from its Phase 1 HEAT clinical trial evaluating 177Lu-RAD202, a radiopharmaceutical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA